Medicare Benefits for Substance Use Disorder and Drug Rehab

Medicare covers substance use disorder treatment more broadly than most beneficiaries realize — and the gap between what's available and what people actually use is wide enough to matter. This page explains what Medicare Parts A, B, and D cover for drug and alcohol treatment, how those benefits interact with different levels of care, and where the coverage edges are.

Definition and scope

Medicare is the federal health insurance program administered by the Centers for Medicare & Medicaid Services (CMS), covering roughly 65 million Americans as of the 2023 CMS enrollment data. Within that program, substance use disorder (SUD) benefits span inpatient detox, outpatient counseling, medication-assisted treatment (MAT), and prescription coverage for FDA-approved addiction medications — all without requiring a separate mental health deductible since the Mental Health Parity and Addiction Equity Act of 2008 extended parity requirements to Medicare Advantage plans.

The key thing to understand about Medicare's structure for drug rehab is that coverage is divided across three parts, and the part that applies depends almost entirely on where and how treatment is delivered.

How it works

Part A covers inpatient treatment delivered in a Medicare-certified hospital or psychiatric facility. This includes medically supervised detoxification when it requires an inpatient admission. The Part A deductible in 2024 is $1,632 per benefit period (CMS Medicare Cost-Sharing), and after 60 days of inpatient care, a daily coinsurance of $408 applies through day 90.

Part B is where outpatient SUD treatment lives. It covers:

Under Part B, beneficiaries typically pay 20% of the Medicare-approved amount after the annual deductible ($240 in 2024). That 20% applies after the deductible is met — no separate SUD cost-sharing track.

Part D covers FDA-approved medications used in MAT, including buprenorphine (Suboxone), naltrexone (Vivitrol), and methadone when dispensed as part of a Part D-enrolled plan. Methadone for opioid use disorder dispensed through an OTP is handled under Part B's bundled OTP benefit, not Part D — a distinction that trips up prescribers and patients alike.

Medicare Advantage (Part C) plans must cover at minimum everything original Medicare covers for SUD, and many cover residential rehab stays that original Medicare does not — a significant structural difference worth checking before assuming coverage levels are identical across plan types.

Common scenarios

Scenario 1: Someone in acute opioid withdrawal needing medical detox. If withdrawal requires IV fluids, cardiac monitoring, or other hospital-level services, Part A covers the inpatient stay at a Medicare-certified facility. If the same person can safely detox in an outpatient setting, Part B applies.

Scenario 2: A beneficiary starting buprenorphine with a primary care physician. The office visits are Part B. The buprenorphine prescription fills through Part D. If that same person enrolls in a certified OTP instead, the entire bundle — counseling, medication, toxicology screening — falls under the 2020 OTP bundled payment through Part B at approximately $161–$203 per week depending on the OTP's payment tier.

Scenario 3: Residential rehab. This is the coverage gap that catches people off guard. Original Medicare generally does not cover standalone residential rehabilitation — the 28- or 30-day residential model most people picture when they hear "drug rehab." Coverage of residential stays, where it exists, typically comes through Medicare Advantage plans with added benefits, or requires the stay to qualify as an inpatient psychiatric admission under Part A criteria. For a full picture of how to get help accessing rehab, the level-of-care determination matters enormously before any admission.

Decision boundaries

The line between what Medicare covers and what it doesn't comes down to three variables: medical necessity documentation, facility certification status, and care setting.

Medical necessity is established by the treating provider using criteria consistent with the American Society of Addiction Medicine (ASAM) levels of care. Without documentation supporting the level of service billed, claims are denied regardless of clinical appropriateness.

Certification status determines eligibility entirely for OTPs — a program must be certified by SAMHSA and enrolled with Medicare to bill under the bundled OTP benefit. A clinically identical program without that certification cannot bill Medicare at all.

Care setting determines which Part applies and, in the case of residential treatment, whether Medicare covers the stay at all. How coverage works in practice depends on whether the facility bills as a hospital outpatient department, a freestanding clinic, or an inpatient psychiatric unit — categories that are invisible to patients but determinative for claims processing.

Medicare Supplement (Medigap) plans can cover the 20% Part B coinsurance and the Part A deductible, substantially reducing out-of-pocket exposure for beneficiaries in intensive treatment. Plan G and Plan N are the two most common Medigap products that interact with SUD costs in a meaningful way.

The frequently asked questions on drug rehab section addresses how Medicare coordinates with Medicaid for dual-eligible beneficiaries — a combination that, when navigated correctly, can reduce cost-sharing to near zero for qualifying individuals enrolled in a Medicare Savings Program.